Alphatec Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Alphatec Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $101.74M | Mar 9, 2018 |
| FY2016 | Dec 31, 2016 | $27.09M | Mar 31, 2017 |
| FY2016 | Sep 30, 2016 | $26.71M | Mar 31, 2017 |
| FY2016 | Jun 30, 2016 | $32.24M | Mar 31, 2017 |
| FY2016 | Mar 31, 2016 | $34.21M | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | $34.79M | Mar 31, 2017 |
| FY2016 | Sep 30, 2015 | $31.69M | Mar 31, 2017 |
| FY2016 | Jun 30, 2015 | $32.33M | Mar 31, 2017 |
| FY2016 | Mar 31, 2015 | $35.58M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $53.63M | Mar 15, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $531.89M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $424.26M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $310.20M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $233.06M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $157.76M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $102.50M | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | $77.59M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $63.24M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $68.22M | Mar 29, 2019 |
| FY2016 | Dec 31, 2016 | $14.63M | Mar 31, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($143.36M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($162.12M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($186.64M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($151.29M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($143.03M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($78.99M) | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | ($57.00M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | ($28.98M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($2.29M) | Mar 29, 2019 |
| FY2016 | Dec 31, 2016 | ($4.35M) | Mar 31, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($82.13M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($136.17M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($173.40M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($146.98M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($128.06M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($58.86M) | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | ($47.28M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | ($22.44M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($9.00M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($15.38M) | Mar 9, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $17.77M | Mar 15, 2016 |
| FY2015 | Dec 31, 2014 | $16.80M | Mar 15, 2016 |
| FY2015 | Dec 31, 2013 | $14.19M | Mar 15, 2016 |
| FY2014 | Dec 31, 2012 | $14.89M | Feb 27, 2015 |
| FY2013 | Dec 31, 2011 | $16.89M | Mar 20, 2014 |
| FY2012 | Dec 31, 2010 | $16.43M | Mar 5, 2013 |
| FY2011 | Dec 31, 2009 | $13.49M | Mar 5, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $498.53M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $450.20M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $374.08M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $300.01M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $229.27M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $129.16M | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | $101.71M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $72.64M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $69.96M | Mar 29, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.23M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($44.65M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($78.49M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($75.13M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($73.32M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($46.41M) | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | ($33.12M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | ($25.61M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($8.73M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($9.96M) | Mar 9, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.46M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $83.22M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $80.51M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $49.45M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $68.54M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $23.13M | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | $13.03M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $6.51M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $7.60M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $8.90M | Mar 9, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $791.21M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $775.71M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $805.21M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $520.97M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $572.05M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $261.22M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $169.95M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $129.48M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $84.66M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $94.19M | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.43M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($14.17M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $78.12M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | ($34.67M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $80.67M | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $129.88M | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $43.63M | Feb 28, 2023 |
| FY2020 | Dec 31, 2018 | $17.57M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | ($26.66M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2016 | ($41.50M) | Mar 29, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.21M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $70.98M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $73.00M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $47.37M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $39.69M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $13.90M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $13.90M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $13.90M | Mar 17, 2020 |
| FY2016 | Dec 31, 2016 | $0 | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | $0 | Mar 31, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.42B) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($1.28B) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($1.12B) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($932.32M) | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | ($781.03M) | Feb 27, 2024 |
| FY2021 | Dec 31, 2020 | ($638.00M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | ($558.92M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | ($501.92M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($459.46M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($457.17M) | Mar 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.81M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $138.84M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $220.97M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $84.70M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $187.25M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $107.77M | Mar 2, 2022 |
| FY2018 | Dec 31, 2018 | $29.05M | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | $22.47M | Mar 29, 2019 |
| FY2018 | Dec 31, 2016 | $19.59M | Mar 29, 2019 |
| FY2015 | Dec 31, 2015 | $11.23M | Mar 15, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $565.94M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $576.18M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $512.84M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $364.46M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $326.83M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $42.17M | Mar 2, 2022 |
| FY2019 | Dec 31, 2019 | $61.23M | Mar 17, 2020 |
| FY2018 | Dec 31, 2018 | $49.31M | Mar 29, 2019 |
| FY2017 | Dec 31, 2017 | $42.87M | Mar 9, 2018 |
| FY2016 | Dec 31, 2016 | $49.27M | Mar 31, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 28, 2023 |
| FY2018 | Dec 31, 2018 | (1) | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | (3) | Mar 9, 2018 |
| FY2015 | Dec 31, 2015 | 0 | Mar 15, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 28, 2023 |
| FY2018 | Dec 31, 2018 | (1) | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | (1) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | (3) | Mar 9, 2018 |
| FY2015 | Dec 31, 2015 | 0 | Mar 15, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 150.26M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 144.13M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 139.25M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 106.64M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 99.54M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 82.10M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | 61.40M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | 43.37M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | 19.86M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 9.05M | Mar 9, 2018 |